These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 26116314)
1. Neuroprotection in Parkinson's disease: a difficult challenge. Stocchi F Lancet Neurol; 2015 Aug; 14(8):780-781. PubMed ID: 26116314 [No Abstract] [Full Text] [Related]
2. Parkinson disease: Laying the foundations for disease-modifying therapies in PD. Brundin P; Wyse R Nat Rev Neurol; 2015 Oct; 11(10):553-5. PubMed ID: 26303855 [TBL] [Abstract][Full Text] [Related]
3. New preclinical model are required to discover neuroprotective compound in Parkinson's disease. Segura-Aguilar J Pharmacol Res; 2017 May; 119():490. PubMed ID: 27894922 [No Abstract] [Full Text] [Related]
4. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315 [TBL] [Abstract][Full Text] [Related]
5. Response to comment by Juan Segura-Aguilar: New preclinical model are required to discover neuroprotective compound in Parkinson's disease. Mattace Raso G; Avagliano C; Calignano A Pharmacol Res; 2017 May; 119():491-492. PubMed ID: 27890814 [No Abstract] [Full Text] [Related]
6. Why hasn't neuroprotection worked in Parkinson's disease? Kieburtz K; Ravina B Nat Clin Pract Neurol; 2007 May; 3(5):240-1. PubMed ID: 17479072 [No Abstract] [Full Text] [Related]
7. Clinical aspects of neuroprotection in Parkinson's disease. Przuntek H J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398 [TBL] [Abstract][Full Text] [Related]
8. [Neuroprotective effect of baicalein in patients with Parkinson's disease]. Yu X; He G; Du G Zhongguo Zhong Yao Za Zhi; 2012 Feb; 37(4):421-5. PubMed ID: 22667137 [TBL] [Abstract][Full Text] [Related]
9. Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. Carta AR; Simuni T Expert Opin Investig Drugs; 2015 Feb; 24(2):219-27. PubMed ID: 25227476 [TBL] [Abstract][Full Text] [Related]
10. Neuroprotective strategies in Parkinson's disease : an update on progress. Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156 [TBL] [Abstract][Full Text] [Related]
11. Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease. Francardo V; Schmitz Y; Sulzer D; Cenci MA Exp Neurol; 2017 Dec; 298(Pt B):137-147. PubMed ID: 28988910 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotection in Parkinson's disease: an elusive goal. Biglan KM; Ravina B Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotection in Parkinson's disease: and now for something completely different? Lang AE Lancet Neurol; 2006 Dec; 5(12):990-1. PubMed ID: 17110271 [No Abstract] [Full Text] [Related]
14. Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection. Gozes I J Mol Neurosci; 2004; 24(3):333-6. PubMed ID: 15655257 [No Abstract] [Full Text] [Related]